Revenue for the quarter increased by 35.2% from the same quarter last year to ₹1,653 crore, which is higher than the CNBC-TV18 poll expectation of ₹1,553.1 crore.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 126% to ₹403 crore. A CNBC-TV18 poll had projected the figure to be ₹368.3 crore.
EBITDA margin for the quarter expanded by more than 1,000 basis points from last year to 24.4%, higher compared to the CNBC-TV18 poll projection of 23.7%. This is the fourth straight quarter that Laurus Labs has reported EBITDA margin in excess of 20%.
Net profit for the period stood at ₹195 crore, while the CNBC-TV18 poll had projected the figure to be ₹147 crore. Laurus Labs had reported a net profit of ₹20 crore in the base quarter.
On Monday, brokerage firm B&K Securities had initiated coverage on Laurus Labs with a "buy" rating and a price target of ₹1,030. The firm said that Laurus Labs is entering a strong growth cycle led by its high-margin CDMO business, which has gradually emerged as the company's key earnings driver.
Shares of Laurus Labs are trading 0.9% higher at ₹932.4. The stock trades close to its record high level of ₹944. Shares of gained 51% so far on a year-to-date basis.
/images/ppid_59c68470-image-176121252677216192.webp)

/images/ppid_59c68470-image-177094778070247070.webp)
/images/ppid_59c68470-image-177094774796122738.webp)
/images/ppid_59c68470-image-177094760561149068.webp)
/images/ppid_59c68470-image-177094753760312086.webp)
/images/ppid_59c68470-image-17709476750941928.webp)
/images/ppid_59c68470-image-177094757431594714.webp)
/images/ppid_59c68470-image-177094764650175790.webp)
/images/ppid_59c68470-image-177094770953263948.webp)
/images/ppid_59c68470-image-177094761449961991.webp)
/images/ppid_59c68470-image-177094753833787776.webp)